News

Thursday April 13, 2023

Audited results for year ended 31 December 2022

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Audited results for the year ended 31 December 2022 Exclusive North American partnering deal worth up to $570m plus royalties secured for […]

Tuesday April 4, 2023

Landmark data published on NTCD-M3

Destiny Pharma plc(“Destiny Pharma” or “the Company”) Landmark data published on successful NTCD‐M3gut colonisation after fidaxomicin administration Brighton, United Kingdom ‐ 4 April 2023 ‐ Destiny Pharma (AIM: DEST), a clinical stage innovative […]

Monday April 3, 2023

Notice of Results and Investor Presentation

Destiny Pharma plc (“Destiny Pharma” or “the Company”)  Notice of Full Year Results and Investor Presentation Brighton, United Kingdom – 3 April 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage […]

Friday March 24, 2023

Landmark XF-73 Phase 2 data published in US journal

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology Demonstrates significant reduction of […]

Thursday March 16, 2023

Neil Clark speaks to Endpoint – ‘UK biotech hands off mid-stage C. difficile...

Destiny Pharma’s CEO, Neil Clark, speaks to Endpoint.  For the full article ‘UK biotech hands off mid-stage C. difficile drug in up to $570M deal’, please click here

Thursday March 16, 2023

Agreement with Sebela Pharmaceuticals for NTCD-M3

Destiny Pharma PLC Exclusive collaboration and co-development agreement for NTCD-M3 with Sebela Pharmaceuticals® worth up to $570m plus royalties Partnership with Sebela will finance the future clinical development and commercialization […]

Thursday March 16, 2023

Issue of Equity

THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) (THIS “ANNOUNCEMENT”) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, […]

Thursday March 16, 2023

Circular to Shareholders

Please click here

Thursday March 16, 2023

Open Offer Application Form

Please click here

Thursday March 16, 2023

Form of Proxy

Please click here